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Background/aim: A cryptogenic elevation of transaminases is the most common hepatic manifestation in celiac disease (CD). In adult
patients and pediatric patients with cryptogenic hypertransaminasemia, the prevalence of CD was 4% and 12%, respectively. However,
there are no related data from China in this regard. We aimed to investigate the status of CD in young Chinese patients with elevated
transaminases.
Materials and methods: A total of 125 patients with elevated transaminases and 125 healthy individuals as controls with matched age
and sex were involved in the study. Serum markers of hepatitis B were determined in patients with elevated transaminases. All subjects
were screened for CD by testing serum IgA antitissue transglutaminase antibodies (anti-tTG IgA), and total serum IgA was determined
in order to rule out IgA deficiency.
Results: None of the subjects were seropositive to IgA anti-tTG antibodies. No association between CD and elevated transaminases was
found. Hepatitis B viral infections were one of the main causes of raised transaminases.
Conclusion: Before the exclusion of every known cause of raised transaminase levels, routine serological screening for CD should not
be recommended for patients who only present elevated transaminases.
Key words: Celiac disease, alanine aminotransferase, aspartate aminotransferases, hepatitis B virus

1. Introduction
Celiac disease (CD) is a T cell-mediated autoimmune
enteropathy induced by the ingestion of gluten proteins,
which exist in grains of wheat, barley, and rye (1). Gluten
can trigger innate and adaptive immunity, which leads to
intestinal epithelial cell impairment, increased mucosal
permeability, villous atrophy, and nutrient malabsorption
(2). Perennial malnutrition can further affect the functions
of other body organs, leading to multisystem disorder.
Liver impairment is one of the common extraintestinal
manifestations of CD, and a wide variety of liver
dysfunctions may occur with celiac disease (3). Among
the liver disorders related to CD, a cryptogenic elevation
of aminotransferases is the most common symptom,
which is an early sign and the only sign in some patients
with CD (3,4). Cryptogenic hypertransaminasemia had
been reported in 27% of adults with CD and in 36% of
children with CD, and in adult patients and pediatric
patients with cryptogenic hypertransaminasemia, the
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prevalence of CD was 4% and 12%, respectively (5,6).
Elevated transaminase levels reverted to normal in the
majority of patients on a gluten free diet (4–6). Therefore,
routine screening for CD is recommended in patients
with elevated aminotransferases of unknown origin, and
it is also considered to be necessary among patients with
abnormal liver function tests (7).
CD has been recently become a public health issue
in many areas of the world, especially in Europe and
the United States (8). CD was considered to be rare
in China (9), and it has not been studied thoroughly,
despite the fact that China is the largest wheat producer
and wheat customer in the world. The consumption of
wheat and other gluten-containing products is increasing
rapidly in China, which carries concomitant risks for the
development of CD. Based on the increased exposure to
gluten and the predisposing HLA allele frequencies in the
Chinese population, CD might be more common in China
than currently reported (10). Moreover, previous studies
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about screening CD in at-risk groups in China found
that the prevalence of CD was 6.5%–11.9% in patients
with chronic diarrhea and 1.77%–8.2% in patients with
diarrhea-predominant irritable bowel syndrome (11–14).
However, there are no related data from China on the
occurrence of CD in patients with elevated transaminases.
Volta et al. reported that elevated transaminases might
be early manifestations in young patients (mean age: 23
years) with asymptomatic CD (4). Therefore, we aimed
to evaluate the necessity of screening for CD in young
patients with elevated transaminases in this study.
2. Materials and methods
2.1. Patients and healthy controls
Subjects with elevated transaminases and controls were
recruited from students who underwent routine physical
examinations at the School Hospital of Nanchang
Hangkong University, Nanchang, China from September
2010 to October 2010. The physical examination records
were collected and investigated. A total of 125 patients with
abnormal liver function tests were enrolled in the study;
all their other physical examination results, including
pulse rate, kidney function tests, and chest X-ray exam,
were normal. As a control group, 125 unrelated healthy
individuals with matched age and sex were also involved.
Heights and weights of all subjects were collected from
their physical examinations records and used to calculate
body mass index (BMI) as kg/m2. BMI values of less than
18.5, between 24 and 27.9, and above 28 are considered
as underweight, overweight, and obese (15), respectively.
All individuals recruited in this study were unrelated
Han Chinese. The study was approved by the institutional
ethics committee, and all subjects gave informed consent
before participation.
2.2. Serological test
Blood samples (5 mL) were collected from all subjects
after at least 10 h of overnight fasting and the avoidance
of excessive exercise and fatigue, alcohol intake, and use of
potential hepatic toxic medications before blood sampling.
After centrifugation at 2130 × g for 5 min, serum samples
were obtained and stored at –80 °C until use. The serum
levels of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were determined again for the
patients with a chemistry analyzer (BS300 chemistry
analyzer, Mindray Medical International Ltd., Shenzhen,
China). The upper limit of normal (ULN) of ALT was
less than 31 IU/L and less than 41 IU/L for females and
males, respectively, while the ULN of AST was <31 IU/L
for females and <37 IU/L for males. Patients with elevated
ALT and/or AST were tested for hepatitis B surface
antigen (HBsAg), antibodies to hepatitis B surface antigen

(anti-HBs), hepatitis B e antigen (HBeAg), antibodies to
hepatitis B e antigen (anti-HBe), and immunoglobulin
G and immunoglobulin M antibodies to hepatitis B core
antigen (IgG and IgM anti-HBc) by enzyme immunoassay
(Autobio Diagnostics Co., Zhengzhou, China).
All of the 250 subjects were screened for CD by testing
serum IgA anti-tissue transglutaminase antibodies (antitTG IgA) with a commercial QUANTA Lite h-tTG IgA
ELISA kit (INOVA Diagnostics, San Diego, CA, USA).
According to the recommendations of the manufacturer,
tTG IgA antibody levels of <20 U were regarded as
negative, 20 to 30 U as weak positive, and >30 U as
moderate to strong positive. All samples were determined
in accordance with the manufacturer’s instructions, and
the total amount of serum IgA was quantified by rate
nephelometry on the IMMAGE 800 immunochemistry
system (Beckman Coulter, Brea, CA, USA) in order to rule
out IgA deficiency.
2.3. Statistical analysis
Data were analyzed using STATA statistical software
(version 11.2, Stata Corp, College Station, TX, USA).
Testing for normality was performed by Shapiro–Wilk test.
Data were expressed as means and standard deviations or
as median and interquartile range (IQR) for continuous
variables as appropriate. For categorical variables, results
were expressed as absolute numbers and percentages.
Significance tests were performed using Student’s t-test or
the Mann–Whitney test for qualitative variables. All tests
were two-sided, and P < 0.05 was considered statistically
significant.
3. Results
A total of 250 subjects were included in this study,
including 125 subjects with elevated liver transaminases
and 125 healthy subjects. Their characteristics are shown
in Table 1. Subjects with elevated transaminases had
higher BMIs than the controls, and 47.2% were overweight
or obese (BMI ≥ 24 kg/m2). However, none of the subjects
were seropositive to IgA anti-tTG antibodies, and the level
of IgA anti-tTG had no significant difference between the
groups. In all subjects, total serum IgA level was normal
without selective IgA deficiency.
Among the 125 subjects with elevated transaminases,
99 (79.2%) had increased levels of ALT and AST, while 26
(20.8%) presented only elevated ALT. Moreover, as shown
in Table 2, a majority of the subjects had mild elevation of
transaminases that were less than 5 times the ULN, and
the AST/ALT ratio was under 1.0 (median: 0.56, IQR:
0.49–0.72). This indicated that hepatitis B viral (HBV)
infections were one of the main causes of abnormal liver
enzymes since 45 subjects (36%) were HBsAg- and/or
HBeAg-positive (Table 3).
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Table 1. Demographic and serological test data of elevated transaminases group and control group.
Characteristics

Elevated transaminases
(n = 125)

Controls
(n = 125)

Female/male

13/112

13/112

Age, mean ± SD (range), years

19 ± 1 (17–21)

19 ± 1 (17–23)

0.908

ALT, median (IQR), U/L

90.6 (61–129.7)

18.3 (12.7–23.9)

<0.0001

AST, median (IQR), U/L

51 (38–69.5)

24.3 (21.3–28.3)

<0.0001

Total IgA, median (IQR), mg/dL

216 (170–270)

194 (147–265)

0.089

Anti-tTG IgA, median (IQR), U

4.03 (3.29–5.19)

4.08 (3.6–5.47)

0.130

Positive anti-tTG IgA, n (%)

0 (0)

0 (0)

BMI, median (IQR), kg/m2

23.4 (20.3–27.7)

19.4 (18.6–21.2)

Underweight (<18.5), n (%)

12 (9.6)

29 (23.2)

Normal (18.5–23.9), n (%)

54 (43.2)

87 (69.6)

Overweight (24–27.9), n (%)

29 (23.2)

9 (7.2)

Obese (≥28), n (%)

30 (24.0)

0 (0)

P-value

<0.0001

BMI, Body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; anti-tTG IgA, immunoglobulin
A antitissue transglutaminase antibodies (cutoff value: >20 U); SD, standard deviation; IQR, interquartile range.
Table 2. Magnitude of transaminase alterations in elevated transaminases group.
Patients with elevated ALTa
(n = 125) n (%)

Patients with elevated ASTb
(n = 99) n (%)

<5 × ULN

109 (87.2)

96 (97.0)

5–10 × ULN

15 (12.0)

3 (3.0)

>10 × ULN

1 (0.8)

0 (0)

Magnitude of transaminases
alteration

ALT, Alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal.
a
ULN: females 31 U/L, males 41 U/L.
b
ULN: females 31 U/L, males 37 U/L.

4. Discussion
Liver function tests are routinely performed for primary
care and diagnosis of liver disease, and ALT and AST are
sensitive markers for hepatic cell damage. Their amounts
can be increased in a spectrum of hepatic dysfunctions
including alcohol-related liver damage, hemochromatosis,
hepatitis B and C, nonalcoholic fatty liver disease (NAFLD),
autoimmune hepatitis, Wilson’s disease, and α1-antitrypsin
deficiency. In addition to hepatic reasons, nonhepatic
causes, e.g., CD, muscular disorders, and thyroid disorders,
can also elevate the levels of transaminase (17,18).
The association between CD and various liver
diseases has been confirmed, including cryptogenic
hypertransaminasemia, autoimmune liver disease
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(autoimmune hepatitis, primary sclerosing cholangitis,
primary biliary cirrhosis), NAFLD, and nonalcoholic
steatohepatitis (3). However, it is still a controversy as to
whether viral hepatitis (HBV and HBC) is associated with
CD (19–22).
In this work, none of patients with elevated
transaminases were positive for serum markers of CD (IgA
anti-tTG antibody), and the association between CD and
elevated transaminases was not addressed. Our finding
is inconsistent with the previously reported studies. The
most possible explanation for the inconsistence might the
different criteria of subject selection in different studies
(4,7,23–25), since the subjects recruited for the evaluation
of the relationship between CD and raised AST/ALT were
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Table 3. The results of hepatitis B serologic tests in elevated transaminases group.
Results of hepatitis B serologic tests

n (%)

Interpretation (16)

HBsAg

anti-HBs

HBeAg

anti-HBe

anti-HBc
(IgG+IgM)

-

-

-

-

-

29 (23.2)

Uninfected and not immune, susceptible

-

+

-

-

+

21 (16.8)

Previously infected and immune due to natural
infection

-

+

-

-

-

11 (8.8)

Clinical recovery, immune due to HBV
vaccination

-

+

-

+

+

7 (5.6)

Recovered from HBV infection

-

-

-

-

+

12 (9.6)

Acute window period, past infection

+

-

-

-

-

4 (3.2)

Early acute HBV infection, chronic HBV
carrier

+

-

-

-

+

1 (0.8)

Acute HBV infection, chronic HBV carrier

+

-

+

-

+

26 (18.4)

Acute HBV infection, chronic active infection,
high infectivity

+

-

-

+

+

14 (11.2)

Convalescence, lower infectivity

+, positive; –, negative
HBsAg, Hepatitis B surface antigen; anti-HBs, antibodies to hepatitis B surface antigen; HBeAg, hepatitis B e antigen; anti-HBe,
antibodies to hepatitis B e antigen; anti-HBc, antibodies to hepatitis B core antigen; HBV, hepatitis B virus; IgG, immunoglobulin G;
IgM, immunoglobulin M.

classified as having unexplained elevated transaminase after
the exclusion of every known cause of raised transaminase
levels, e.g., alcohol or drug use, viral hepatitis, metabolic
hepatic disease, and autoimmune liver diseases (4,23–25).
Only a study conducted in Iran studied the necessity of
routine screening for CD in patients with abnormal liver
function tests irrespective of the reason for abnormal liver
function tests (7), and 6 patients were diagnosed with
CD among 224 patients with abnormal liver function.
Those 6 patients had hypertransaminasemia, autoimmune
hepatitis, and cryptogenic cirrhosis, respectively (7).
In the case of interference, alcohol, medications,
and strenuous exercise, which can affect the level of
transaminases, were first ruled out by inquiring. Moreover,
since the prevalence of HBsAg is 7.2% in China (26), and
HBV infection is one of most common causes of elevated
transaminases, we performed further hepatitis B serologic
tests in the patients with elevated transaminases. The test
showed that 45 patients (36%) carried HbsAg, and this
indicated that the main cause of elevated transaminases in
these patients was HBV infection. However, the previous
reported studies showed obscure associations between
HBV and CD. Two groups from southern Iran (19) and
Brazil (20) showed that the prevalence of definite CD by

duodenal biopsy in HBV patients was 5.4% and 9.1%,
respectively, suggesting the necessity of screening for CD
in patients with HBV. On the contrary, information from
both Italy (21) and the Czech Republic (22) showed that
none of the patients with HBV were diagnosed with CD,
which was consistent with our findings. In addition, the
majority of patients had mildly elevated transaminases
levels and AST/ALT ratios of less than 1, and 24% of
patients were obese in the current study. As we know,
metabolic syndrome and obesity are correlated with
NAFLD, and NAFLD cases also have mildly elevated ALT
and AST with low AST/ALT ratios (<1) (27). NAFLD and
metabolic syndrome were two main causes of abnormal
liver tests among the Chinese population (28). Therefore,
the most probable cause of elevated transaminases is
NAFLD or metabolic syndrome in the patients recruited
in this study, in addition to HBV infection.
The small sample size of the study could lead to bias of
the results. In particular, the female-to-male ratio is low at
only about 1:10, because previous studies had identified
that the occurrence of CD in women is 2 to 3 times higher
than in men (8,29,30). Obviously, we cannot claim that
elevated transaminases have nothing to do with CD,
although none of the patients with elevated transaminases
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were seropositive for CD in this work. However, we think
that serological screening for CD in a routine way should
not be recommended for patients who only present
elevated transaminases. Patients with only elevated
transaminases need to be followed and reevaluated, and
the identification of causes leading to elevated ALT and/or
AST is very important if persistent transaminases increase.
Screening for CD is recommended only for patients with
unexplained elevated transaminase.
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